恒瑞医药HER2 ADC创新药注射用瑞康曲妥珠单抗全国首批发货

恒瑞医药
09 Jun

2025年6月8日,恒瑞医药子公司苏州盛迪亚生物医药有限公司自主研发的1类新药注射用瑞康曲妥珠单抗(艾维达®)首批发货仪式在苏州盛迪亚生产基地隆重举行,这是国内首个获批用于HER2突变NSCLC患者的中国自主研发抗体偶联药物(ADC),首批药品将迅速覆盖全国多个医疗机构,为广大患者带来精准治疗的新希望。近日,公司自主研发的HER2 ADC、1类新药注射用瑞康曲妥珠单抗(商品名:艾维达®)获批上市,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10